237 related articles for article (PubMed ID: 26429753)
1. Effect of melatonin on sleep disorders in a monkey model of Parkinson's disease.
Belaid H; Adrien J; Karachi C; Hirsch EC; François C
Sleep Med; 2015 Oct; 16(10):1245-51. PubMed ID: 26429753
[TBL] [Abstract][Full Text] [Related]
2. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
[TBL] [Abstract][Full Text] [Related]
3. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
4. Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion.
Belaid H; Adrien J; Laffrat E; Tandé D; Karachi C; Grabli D; Arnulf I; Clark SD; Drouot X; Hirsch EC; François C
J Neurosci; 2014 Jul; 34(27):9124-33. PubMed ID: 24990932
[TBL] [Abstract][Full Text] [Related]
5. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism.
Naskar A; Manivasagam T; Chakraborty J; Singh R; Thomas B; Dhanasekaran M; Mohanakumar KP
J Pineal Res; 2013 Oct; 55(3):304-12. PubMed ID: 23952687
[TBL] [Abstract][Full Text] [Related]
6. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
[TBL] [Abstract][Full Text] [Related]
7. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
Ko WK; Li Q; Bezard E
Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
[TBL] [Abstract][Full Text] [Related]
8. [Sleep disorders in Parkinson's disease without dementia: a comparative randomized controlled study of melatonin and clonazepam].
Litvinenko IV; Krasakov IV; Tikhomirova OV
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(12):26-30. PubMed ID: 23388588
[TBL] [Abstract][Full Text] [Related]
9. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
[TBL] [Abstract][Full Text] [Related]
10. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
Ando K; Inoue T; Itoh T
Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
[TBL] [Abstract][Full Text] [Related]
11. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
[TBL] [Abstract][Full Text] [Related]
12. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
13. Subthalamotomy-induced changes in dopamine receptors in parkinsonian monkeys.
Jourdain VA; Morin N; Morissette M; Grégoire L; Di Paolo T
Exp Neurol; 2014 Nov; 261():816-25. PubMed ID: 25172808
[TBL] [Abstract][Full Text] [Related]
14. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study.
Medeiros CA; Carvalhedo de Bruin PF; Lopes LA; Magalhães MC; de Lourdes Seabra M; de Bruin VM
J Neurol; 2007 Apr; 254(4):459-64. PubMed ID: 17404779
[TBL] [Abstract][Full Text] [Related]
15. Levodopa partially rescues microglial numerical, morphological, and phagolysosomal alterations in a monkey model of Parkinson's disease.
Lecours C; St-Pierre MK; Picard K; Bordeleau M; Bourque M; Awogbindin IO; Benadjal A; Ibanez FG; Gagnon D; Cantin L; Parent M; Di Paolo T; Tremblay ME
Brain Behav Immun; 2020 Nov; 90():81-96. PubMed ID: 32755645
[TBL] [Abstract][Full Text] [Related]
16. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
[TBL] [Abstract][Full Text] [Related]
17. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
Koprich JB; Fox SH; Johnston TH; Goodman A; Le Bourdonnec B; Dolle RE; DeHaven RN; DeHaven-Hudkins DL; Little PJ; Brotchie JM
Mov Disord; 2011 Jun; 26(7):1225-33. PubMed ID: 21465551
[TBL] [Abstract][Full Text] [Related]
18. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
Di Paolo T; Grégoire L; Feuerbach D; Elbast W; Weiss M; Gomez-Mancilla B
Parkinsonism Relat Disord; 2014 Nov; 20(11):1119-23. PubMed ID: 25172125
[TBL] [Abstract][Full Text] [Related]
19. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Huot P; Johnston TH; Koprich JB; Aman A; Fox SH; Brotchie JM
J Pharmacol Exp Ther; 2012 Aug; 342(2):576-85. PubMed ID: 22619253
[TBL] [Abstract][Full Text] [Related]
20. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
Neuropharmacology; 2012 Oct; 63(5):829-36. PubMed ID: 22722022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
